HIV/AIDS
-
Kenya begins nationwide rollout of revolutionary HIV prevention injectable Lenacapavir
The initial rollout will target 152 health facilities across 15 high-burden counties, following a carefully structured, phased approach.
-
Shionogi increases stake in ViiV Healthcare as Pfizer exits HIV venture in USD2.13B deal
The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.
-
Rwanda to roll out long-acting HIV prevention injection Lenacapavir by the end of 2026
The introduction of lenacapavir will expand rather than replace current prevention methods available in Rwanda.
-
Kenya’s Health Ministry clears Lenacapavir to tackle pill fatigue for HIV patients
The Pharmacy and Poisons Board has approved both the 300 mg tablet and 464 mg injectable solution forms of Lenacapavir for use as pre-exposure prophylaxis (PrEP).
-
IMPALA Study finds two-monthly injectable HIV treatment safe and preferred by African patients
Results showed that the injectable regimen performed just as well as the daily oral dolutegravir-based therapy (TLD) but helped reduce the burden of daily medication.
-
Nigeria meets two of three global 95-95-95 HIV targets, moves closer to Ending AIDS by 2030
This progress was announced by Dr. Temitope Ilori, the Director-General of the National Agency for the Control of AIDS (NACA), during the World AIDS Day 2025 observance in Abuja.